NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 85 Price disclosure requirements [100%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 13 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 84 Originator brands [57%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 6 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 5 Interpretation [28%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 41 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 70 Method for determining weighted average disclosed price of listed brand of pharmaceutical item [28%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 3 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 85C Stockholding disclosure requirements [28%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 9 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 65A Price reductions for single brands of combination items [14%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 12 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 85A Flow on price reductions for brands of combination items [14%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 13 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - REG 103 Application provision relating to the National Health (Pharmaceutical Benefits) Amendment (2021 Measures No. 1) Regulations 2021 [14%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 5 KB)   

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 2017 - NOTES [14%]
(From Commonwealth Consolidated Regulations; 1 January 2017; 89 KB)